Literature DB >> 15119549

A deficiency of CD4+CD25+ T cells permits the development of spontaneous lupus-like disease in mice, and can be reversed by induction of mucosal tolerance to histone peptide autoantigen.

H Y Wu1, N A Staines.   

Abstract

It has been repeatedly shown that a subset of CD4+ T cells that constitutively express CD25 on their surface plays a role in the maintenance of self-tolerance. They may directly or indirectly affect the development of autoimmunity in susceptible mice and humans. In this study, we examine the relationship between the percentage of peripheral CD4+CD25+ T cells and the state of disease in spontaneous models of autoimmune disease. We found that both BWF1 and SNF1 mice that spontaneously develop a lupus-like disease have inherently lower percentage of the CD4+CD25+ T cells in their CD4 repertoire compared with normal Balb/c and DBA/1 mice. The percentage of CD4+CD25+ T cells was found to be increased in both normal and lupus-prone mice as they reached 7 to 8 months of age. However, mice with an autoimmune background differed from mice on a normal background in that the number of CD4+CD25+ T cells never reached 5% of the CD4 population. The lower number of the CD4+CD25+ T cells in autoimmune mice was restored to the level seen in normal mice following administration of histone peptide H471 or OVA(323-339) peptide in the absence of adjuvant intranasally but not intradermally. As such transmucosal treatment may ameliorate disease, we conclude that a deficiency in the CD4+CD25+ T cell pool contributes to a susceptibility to develop spontaneous lupus disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15119549     DOI: 10.1191/0961203303lu1002oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  32 in total

Review 1.  Dendritic cells: potential triggers of autoimmunity and targets for therapy.

Authors:  J A Hardin
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

2.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

3.  Autoantibody production in lpr/lpr gld/gld mice reflects accumulation of CD4+ effector cells that are resistant to regulatory T cell activity.

Authors:  Brian D Hondowicz; Michele L Fields; Simone A Nish; Joseph Larkin; Andrew J Caton; Jan Erikson
Journal:  J Autoimmun       Date:  2008-06-09       Impact factor: 7.094

4.  A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.

Authors:  Amir Sharabi; Heidy Zinger; Maya Zborowsky; Zev M Sthoeger; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

5.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

6.  Regulatory T cell subsets in children with systemic lupus erythematosus.

Authors:  Azza A Eltayeb; Douaa M Sayed; Noha A Afifi; Maggie A Ibrahim; Tahra M Sheref
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

7.  Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus.

Authors:  Wen-Xian Li; Hai-Feng Pan; Jian-Li Hu; Chang-Zhong Wang; Ning Zhang; Jing Li; Xiang-Pei Li; Jian-Hua Xu; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2009-12-10       Impact factor: 2.980

8.  Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.

Authors:  Diana Milojevic; Khoa D Nguyen; Diane Wara; Elizabeth D Mellins
Journal:  Pediatr Rheumatol Online J       Date:  2008-12-01       Impact factor: 3.054

Review 9.  Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

Authors:  Fanny Monneaux; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

Review 10.  [Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance].

Authors:  K Ohl; K Tenbrock
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.